Availability and financing of CAR-T cell therapies: A cross-country comparative analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Health Policy (149:) - Amsterdam : Elsevier - Art.-Id. 105153
- Ereignis
-
Veröffentlichung
- (wo)
-
Berlin
- (wer)
-
Technische Universität Berlin
- (wann)
-
2024
- Urheber
-
Litvinova, Yulia
Merkur, Sherry
Allin, Sara
Angulo-Pueyo, Ester
Behmane, Daiga
Bernal-Delgado, Enrique
Dalmas, Miriam
De Belvis, Antonio
Edwards, Nigel
Estupiñán-Romero, Francisco
Gaal, Peter
Gerkens, Sophie
Jamieson, Margaret
Morsella, Alisha
Picecchi, Dario
Røshol, Hilde
Saunes, Ingrid Sperre
Sullivan, Terry
Szécsényi-Nagy, Balázs
Vijver, Inneke Van De
Walter, Ricciardi
Panteli, Dimitra
- DOI
-
10.14279/depositonce-21406
- Handle
-
11303/22605
- URN
-
urn:nbn:de:101:1-2409250157273.626909376605
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Litvinova, Yulia
- Merkur, Sherry
- Allin, Sara
- Angulo-Pueyo, Ester
- Behmane, Daiga
- Bernal-Delgado, Enrique
- Dalmas, Miriam
- De Belvis, Antonio
- Edwards, Nigel
- Estupiñán-Romero, Francisco
- Gaal, Peter
- Gerkens, Sophie
- Jamieson, Margaret
- Morsella, Alisha
- Picecchi, Dario
- Røshol, Hilde
- Saunes, Ingrid Sperre
- Sullivan, Terry
- Szécsényi-Nagy, Balázs
- Vijver, Inneke Van De
- Walter, Ricciardi
- Panteli, Dimitra
- Technische Universität Berlin
Entstanden
- 2024
Ähnliche Objekte (12)
CAR-T cell combination therapies in hematologic malignancies
CAR-T Therapies in Solid Tumors: Opportunities and Challenges
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice
Disparities in Clinical Trial Enrollment– Focus on CAR-T and Bispecific Antibody Therapies
Cross-country differences in the contribution of future migration to old-age financing
CARt
CARt
CART
CARt
"CARt*
CAR-T cell combination therapies in hematologic malignancies
CAR-T Therapies in Solid Tumors: Opportunities and Challenges
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice
Disparities in Clinical Trial Enrollment– Focus on CAR-T and Bispecific Antibody Therapies
Cross-country differences in the contribution of future migration to old-age financing
CARt
CARt
CART
CARt
"CARt*
CAR-T cell combination therapies in hematologic malignancies
CAR-T Therapies in Solid Tumors: Opportunities and Challenges
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice
Disparities in Clinical Trial Enrollment– Focus on CAR-T and Bispecific Antibody Therapies
Cross-country differences in the contribution of future migration to old-age financing
CARt
CARt
CART
CARt